日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Inhibition of the growth of patient-derived pancreatic cancer xenografts with the MEK inhibitor trametinib is augmented by combined treatment with the epidermal growth factor receptor/HER2 inhibitor lapatinib.

MEK 抑制剂曲美替尼对患者来源的胰腺癌异种移植瘤生长的抑制作用,可通过与表皮生长因子受体/HER2 抑制剂拉帕替尼联合治疗得到增强

Walters Dustin M, Lindberg James M, Adair Sara J, Newhook Timothy E, Cowan Catharine R, Stokes Jayme B, Borgman Cheryl A, Stelow Edward B, Lowrey Bryce T, Chopivsky Maria E, Gilmer Tona M, Parsons John T, Bauer Todd W